Rubraca 250 mg film-coated tablets

DRUG4 trials

Sponsors

Bristol-Myers Squibb Services Unlimited Company, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, pharmaand GmbH

Conditions

Advanced (stage III B-C-IV) ovarianAdvanced solid tumorFallopian tube cancerMalignant peritoneal neoplasmMultiple myelomaNon-Hodgkin lymphomaOvarian epithelial cancerPan tumor

Phase 2

A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)

RecruitingCTIS2023-509152-33-00

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAdvanced solid tumor, Multiple myeloma, Non-Hodgkin lymphoma +1

Start: 2016-07-25Target: 3000Updated: 2025-12-19

Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies

RecruitingCTIS2023-506914-32-00

Bristol-Myers Squibb Services Unlimited CompanyPan tumor

Start: 2020-05-05Target: 307Updated: 2026-01-19

MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib, selected according to HRD status, in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination

Active, not recruitingCTIS2024-516632-99-00

Fondazione Policlinico Universitario Agostino Gemelli IRCCSAdvanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer.

Start: 2021-03-17Target: 300Updated: 2025-06-10

Phase 3

ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Active, not recruitingCTIS2024-516662-11-00

pharmaand GmbHadvanced (FIGO stage III-IV), fallopian tube, Fallopian tube cancer +4

Start: 2018-11-23Target: 257Updated: 2026-01-19

Related Papers

Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol.

2025-12-01

Data from Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol

2025-12-01